Zephyr Endobronchial Valve System
Pulmonx Corporation · Decision date Jun 29, 2018
What did the FDA approve?
FDA records P180002 as an original PMA application. The recorded decision is approval, dated Jun 29, 2018.
FDA approval order statement
Approval of the Pulmonx Zephyr Endobronchial Valve System. The device is an implantable bronchial valve indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Anesthesiology
- Decision date
- Jun 29, 2018
Regulatory record facts
- Identifier
- P180002
- Regulatory pathway
- Premarket approval application
- Applicant
- Pulmonx Corporation
- Product code
- NJK
- Decision code
- APPR
- Decision date
- Jun 29, 2018
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Valve, pulmonary.
- Applicant
- Pulmonx Corporation
- Product code
- NJK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P180002 received
Application receipt date recorded by FDA.
P180002 · FDA decision
APPR
P180002/S032 · Related supplement
Zephyr Endobronchial Valve System
Timeline entries are records held by MedtechLedger for P180002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Zephyr Endobronchial Valve SystemP180002/S032 | Pulmonx Corporation | PMA supplement | Sep 11, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pulmonx Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 700 Chesapeake Dr., Redwood City, CA, 94063
Sources and methodology
- Original FDA record: P180002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records